Fate Therapeutics, Inc. is a leading pharmaceutical company in the United States that focuses on developing cutting-edge cellular immunotherapies for cancer and autoimmune diseases. With a Risk Rating Score of 27.8, the company is deemed to have a medium risk assessment. Their innovative programs include NK- and T-cell immuno-oncology programs as well as immuno-regulatory programs. Utilizing clonal master iPSC lines, Fate Therapeutics is at the forefront of creating off-the-shelf engineered product candidates to revolutionize the treatment of these life-threatening conditions. Explore the groundbreaking work of Fate Therapeutics, Inc. and discover the future of ESG-focused pharmaceuticals.